Ispire Technology Inc. (ISPR.US) announced today the formation of a joint venture with global pharmaceutical company Shandong Jincheng Pharmaceutical Group Co.,Ltd. (300233.SZ) to jointly produce and commercialize nicotine pouch products. This partnership marks Ispire's official entry into the rapidly expanding nicotine pouch market, broadening its product portfolio beyond its existing vaporization hardware and enabling participation in one of the fastest-growing segments of the global nicotine market. According to Grand View Research, the global nicotine pouch market is valued at approximately $7 billion in 2025 and is projected to grow at a compound annual growth rate of nearly 25%, potentially exceeding $40 billion by 2033.
"This joint venture represents a significant strategic expansion for Ispire," stated Michael Wang, Co-CEO of Ispire. "Nicotine pouches are a high-growth global category, and this collaboration allows us to enter the market with ready operational capabilities and pharmaceutical-grade expertise. We believe this will become a major new revenue stream and a natural extension of our broader nicotine innovation strategy."
Under the agreement terms, Shandong Jincheng Pharmaceutical Group Co.,Ltd. will provide the joint venture with production equipment, process technology, production quality control systems, and high-quality nicotine pouch filler materials. This support will enable the project to commence operations almost immediately, facilitating the rapid achievement of production scale and revenue. The joint venture is expected to leverage Ispire's strengths in precise dosage control, regulatory compliance, and global distribution to create differentiated nicotine pouch products in an increasingly competitive market.
"Ispire's manufacturing excellence and robust global regulatory systems will accelerate the commercialization process for this joint venture," said Mr. Li Jiaquan, Chairman and President of Shandong Jincheng Pharmaceutical Group Co.,Ltd. "By combining our over two decades of pharmaceutical technology expertise with Ispire's operational capabilities to develop markets in Europe, America, the Middle East, and Southeast Asia, we are positioned to rapidly and compliantly scale up the production of high-quality nicotine pouches."
Shandong Jincheng Pharmaceutical Group Co.,Ltd. is a diversified pharmaceutical enterprise with approximately 3,800 employees and over 30 affiliated companies worldwide. The company is primarily engaged in the research and development, production, and commercialization of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), finished drugs, and health products. The company anticipates that initial production will be supported by existing commercial relationships and plans to further explore business development opportunities in the oral nicotine sector as part of its broader international nicotine platform strategy.
This expansion builds upon Ispire's ongoing strategy to diversify its product portfolio across various reduced-harm nicotine product formats, while fully utilizing its manufacturing scale, compliance capabilities, and global distribution network.
Comments